INM insider transaction filings
InMed Pharmaceuticals Inc. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-09-16. Screen INM transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 4 Form 4 filings. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 16 legs across 4 filings by 6 insiders — 119,198 shares, $161,625 total (shares × price as filed).
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 0.
- Largest priced transaction: purchase of 54,256 shares @ $1.30 ($70,446) by ADAR1 Capital Management, LLC, filed 2026-09-16.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| ADAR1 Capital Management, LLC — 10% owner & Schneeberger Daniel — 10% owner | 2 | 4 legs · 92,101 sh · $119,631 | — | — |
| Vivo Opportunity, LLC — 10% owner & Vivo Opportunity Fund Holdings, L.P. — 10% owner & Vivo Opportunity Cayman, LLC — 10% owner & Vivo Opportunity Cayman Fund, L.P. — 10% owner | 2 | 12 legs · 27,097 sh · $41,994 | — | — |
Recent Form 4 filings — InMed Pharmaceuticals Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-16 | 4 | ADAR1 Capital Management, LLC — 10% owner Schneeberger Daniel — 10% owner | Purchase (P): 28,505 @ $1.29 · Purchase (P): 54,256 @ $1.30 · Purchase (P): 8,340 @ $1.29 | EDGAR |
| 2026-07-17 | 4 | ADAR1 Capital Management, LLC — 10% owner Schneeberger Daniel — 10% owner | Purchase (P): 1,000 @ $1.55 | EDGAR |
| 2026-07-16 | 4 | Vivo Opportunity, LLC — 10% owner Vivo Opportunity Fund Holdings, L.P. — 10% owner Vivo Opportunity Cayman, LLC — 10% owner Vivo Opportunity Cayman Fund, L.P. — 10% owner | Purchase (P): 4,882 @ $1.55 · Purchase (P): 493 @ $1.55 · Purchase (P): 13,761 @ $1.55 · Purchase (P): 1,389 @ $1.55 · Purchase (P): 19 @ $1.55 · Purchase (P): 2 @ $1.55 | EDGAR |
| 2026-07-02 | 4 | Vivo Opportunity, LLC — 10% owner Vivo Opportunity Fund Holdings, L.P. — 10% owner Vivo Opportunity Cayman, LLC — 10% owner Vivo Opportunity Cayman Fund, L.P. — 10% owner | Purchase (P): 545 @ $1.54 · Purchase (P): 55 @ $1.54 · Purchase (P): 3,946 @ $1.55 · Purchase (P): 398 @ $1.55 · Purchase (P): 1,460 @ $1.55 · Purchase (P): 147 @ $1.55 | EDGAR |
| 2026-06-10 | 4 | Vivo Opportunity, LLC — 10% owner Vivo Opportunity Fund Holdings, L.P. — 10% owner Vivo Opportunity Cayman, LLC — 10% owner Vivo Opportunity Cayman Fund, L.P. — 10% owner | Purchase (P): 51,056 @ $1.56 · Purchase (P): 5,154 @ $1.56 · Purchase (P): 30,882 @ $1.69 · Purchase (P): 3,118 @ $1.69 · Purchase (P): 16,164 @ $1.57 · Purchase (P): 1,632 @ $1.57 · +12 more | EDGAR |
| 2026-05-21 | 4 | ADAR1 Capital Management, LLC — 10% owner Schneeberger Daniel — 10% owner | Purchase (P): 68,551 @ $1.60 · Purchase (P): 200,000 @ $1.56 · Purchase (P): 200,000 @ $1.50 | EDGAR |
| 2025-12-19 | 4 | Johnson Shane Aaron — Sr VP & General Manager | Grant/award (A): 8,500 (derivative) @ $0 | EDGAR |
| 2025-12-19 | 4 | Lemerond Nicole — Director | Grant/award (A): 1,750 (derivative) @ $0 | EDGAR |
| 2025-12-19 | 4 | Klompas Neil A — Director | Grant/award (A): 1,750 (derivative) @ $0 | EDGAR |
| 2025-12-19 | 4 | Jagpal Netta — Chief Financial Officer | Grant/award (A): 18,000 (derivative) @ $0 | EDGAR |
| 2025-12-19 | 4 | WOUDENBERG MICHAEL — Chief Operating Officer | Grant/award (A): 18,000 (derivative) @ $0 | EDGAR |
| 2025-12-19 | 4 | Bathery John Steven — Director | Grant/award (A): 1,750 (derivative) @ $0 | EDGAR |
| 2025-12-19 | 4 | HSU ERIC C — Sr. VP, Pre-Clinical Res/Dev | Grant/award (A): 13,000 (derivative) @ $0 | EDGAR |
| 2025-12-19 | 4 | ADAMS ERIC A — President & CEO, Director | Grant/award (A): 35,000 (derivative) @ $0 | EDGAR |
| 2025-12-19 | 4 | HULL ANDREW — Director | Grant/award (A): 1,750 (derivative) @ $0 | EDGAR |
| 2025-12-17 | 4 | HULL ANDREW — Director | Code (H): 14 (derivative) @ $0 | EDGAR |
| 2025-12-17 | 4 | ADAMS ERIC A — President & CEO, Director | Code (H): 250 (derivative) @ $0 | EDGAR |
| 2025-12-17 | 4 | WOUDENBERG MICHAEL — Chief Operating Officer | Code (H): 60 (derivative) @ $0 | EDGAR |
| 2025-12-17 | 4 | HSU ERIC C — Sr. VP, Pre-Clinical Res/Dev | Code (H): 70 (derivative) @ $0 | EDGAR |
| 2025-10-21 | 4 | Klompas Neil A — Director | Grant/award (A): 3,500 (derivative) @ $0 | EDGAR |
| 2025-02-03 | 4 | HULL ANDREW — Director | Code (H): 2 (derivative) @ $0 | EDGAR |
| 2024-12-23 | 4 | HSU ERIC C — Sr. VP, Pre-Clinical Res/Dev | Grant/award (A): 2,750 (derivative) @ $0 | EDGAR |
| 2024-12-23 | 4 | Baldasare Bryan T — Director | Grant/award (A): 550 (derivative) @ $0 | EDGAR |
| 2024-12-23 | 4 | Johnson Shane Aaron — Sr VP & General Manager | Grant/award (A): 1,500 (derivative) @ $0 | EDGAR |
| 2024-12-23 | 4 | Jagpal Netta — Chief Financial Officer | Grant/award (A): 3,750 (derivative) @ $0 | EDGAR |
| 2024-12-23 | 4 | Lemerond Nicole — Director | Grant/award (A): 550 (derivative) @ $0 | EDGAR |
| 2024-12-23 | 4 | WOUDENBERG MICHAEL — Chief Operating Officer | Grant/award (A): 3,750 (derivative) @ $0 | EDGAR |
| 2024-12-23 | 4 | ADAMS ERIC A — President & CEO, Director | Grant/award (A): 6,250 (derivative) @ $0 | EDGAR |
| 2024-12-23 | 4 | HULL ANDREW — Director | Grant/award (A): 550 (derivative) @ $0 | EDGAR |
| 2024-12-23 | 4 | Grove Janet P — Director | Grant/award (A): 550 (derivative) @ $0 | EDGAR |
| 2024-08-02 | 4 | MANCINI ALEXANDRA DIANE JANET | Sale (S): 240 @ $0.18 | EDGAR |
| 2024-05-28 | 4 | WOUDENBERG MICHAEL — Chief Operating Officer | Code (H): 394 (derivative) @ $0 | EDGAR |
| 2024-05-28 | 4 | HSU ERIC C — Sr. VP, Pre-Clinical Res/Dev | Code (H): 545 (derivative) @ $0 | EDGAR |
| 2024-05-28 | 4 | ADAMS ERIC A — President & CEO, Director | Code (H): 1,139 (derivative) @ $0 | EDGAR |
| 2024-05-28 | 4 | MANCINI ALEXANDRA DIANE JANET — Sr VP, Clinical Reg Affairs | Code (H): 485 (derivative) @ $0 | EDGAR |
| 2024-03-05 | 4 | HULL ANDREW — Director | Code (H): 42 (derivative) @ $0 | EDGAR |
| 2024-03-05 | 4 | HSU ERIC C — Sr. VP, Pre-Clinical Res/Dev | Code (H): 309 (derivative) @ $0 | EDGAR |
| 2024-03-05 | 4 | MANCINI ALEXANDRA DIANE JANET — Sr VP, Clinical Reg Affairs | Code (H): 121 (derivative) @ $0 | EDGAR |
| 2024-02-22 | 4 | HULL ANDREW — Director | Purchase (P): 37,500 @ $0.39 | EDGAR |
| 2024-02-21 | 4 | ADAMS ERIC A — President & CEO, Director | Purchase (P): 41,600 @ $0.36 | EDGAR |
| 2023-12-26 | 4 | Johnson Shane Aaron — Sr VP & General Manager | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2023-12-26 | 4 | Lemerond Nicole — Director | Grant/award (A): 7,100 (derivative) @ $0 | EDGAR |
| 2023-12-26 | 4 | WOUDENBERG MICHAEL — Chief Operating Officer | Grant/award (A): 65,000 (derivative) @ $0 | EDGAR |
| 2023-12-26 | 4 | Tegge Jonathan — Interim CFO | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2023-12-26 | 4 | HSU ERIC C — Sr. VP, Pre-Clinical Res/Dev | Grant/award (A): 45,000 (derivative) @ $0 | EDGAR |
| 2023-12-26 | 4 | ADAMS ERIC A — President & CEO, Director | Grant/award (A): 136,000 (derivative) @ $0 | EDGAR |
| 2023-12-26 | 4 | Baldasare Bryan T — Director | Grant/award (A): 7,100 (derivative) @ $0 | EDGAR |
| 2023-12-26 | 4 | MANCINI ALEXANDRA DIANE JANET — Sr VP, Clinical Reg Affairs | Grant/award (A): 45,000 (derivative) @ $0 | EDGAR |
| 2023-12-26 | 4 | HULL ANDREW — Director | Grant/award (A): 7,100 (derivative) @ $0 | EDGAR |
| 2023-12-26 | 4 | Grove Janet P — Director | Grant/award (A): 7,100 (derivative) @ $0 | EDGAR |
Recent 8-K events — InMed Pharmaceuticals Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-09-18 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-22 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-10 | 8-K | 1.01 — Entry into a Material Definitive Agreement 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-10 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-19 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.03 — Material Modification to Rights of Security Holders 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-19 | 8-K | 1.01 — Entry into a Material Definitive Agreement 5.01 — Changes in Control of Registrant 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-07 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-27 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.03 — Material Modification to Rights of Security Holders 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-03 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-30 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=INM returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →